Our mission is to provide trustworthy and universal access to state-of-the-art total solutions to treat structural heart diseases

MicroPort CardioFlow adheres to the vision of building a people centric enterprise ranking as a global leader of evolving and emerging medical technologies

MicroPort CardioFlow Medtech Corporation(微创心通医疗科技有限公司)(the “Company”) is a medical device company in China focusing on research, development and commercialization of innovative transcatheter and surgical solutions for valvular heart diseases, which has several subsidiaries including Shanghai MicroPort CardioFlow Medtech Company Limited (collectively "MicroPort CardioFlow" or "the Group").
Our self-developed first-generation transcatheter aortic valve implantation (“TAVI”) product VitaFlow™ was approved by the NMPA in July 2019 and subsequently commercialized in China in August 2019. Our second generation product VitaFlow Liberty™ was approved by the NMPA in August 2021 in China. Currently VitaFlow Liberty™ is also under clinical trial in Europe,we have applied for CE Mark of VitaFlow Liberty™ on December 2021.

VitaFlow® Aortic Valve System

 

On August 28, 2019, the first implantation of the self-developed VitaFlow® Aortic Valve System of MicroPort CardioFlow was performed at Zhongshan Hospital affiliated to Fudan University. Prof. Ge Junbo, Academician of Chinese Academy of Sciences, Director of the Cardiology Department of Zhongshan Hospital, performed the surgery and successfully implanted the VitaFlow® aortic valve into a 70-year-old male patient.

Since the launch of VitaFlow® series of TAVI products, MicroPort CardioFlow has entered into over 300 heart centers across China, becoming a major player in the Chinese heart valve market.

 

 

Clinical Solutions

Learn more

 

Aortic stenosis is one of the most common and serious valvular diseases. Transcatheter aortic valve implantation (TAVI) as a clinical interventional therapy, provides an ideal alternative treatment for critically ill patients with aortic stenosis who can not tolerate valve replacement through surgical means. With the increasing aging of the population and the expansion of the TAVI indications.

 

“Because Every Moment Matters”

MicroPort CardioFlow’s Strategic Partner 4C Medical Technologies Completed Multiple TMVR Procedures with AltaValve™ Using the Next Generation Low Profile Fully Retrievable Transseptal Delivery System

The procedures were performed by Dr. Vlasis Ninios, Director of Department of Cardiology at the Interbalken Medical Center in Thessaloniki, Greece.

3
2022.05

CardioFlow Medtech Announces Annual Results for 2021

Shanghai, China, 29 March 2022 - MicroPort CardioFlow today announced the annual results of the Company and its subsidiaries for the 12 months ended December 31, 2021. In the Reporting Period, MicroPort CardioFlow recorded revenue of RMB200.8 million, representing a year-on-year growth of 93.2%. In addition to the significant growth in revenue, the gross profit margin also improved drastically by 15.4 percentage points to 59.1%.

31
2022.03

VitaFlow Liberty™ by MicroPort CardioFlow Obtains Approval in Argentina

MicroPort CardioFlow recently announced that its transcatheter aortic valve implantation (TAVI) solution, the new-generation VitaFlow Liberty™ Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty™) has received marketing approval by the Argentine National Administration of Drugs, Foods, and Medical Devices (ANMAT).

7
2022.01

Join Us, to create a better tomorrow for more people across the globe